Ignite Creation Date:
2025-12-24 @ 7:09 PM
Ignite Modification Date:
2026-01-01 @ 9:08 AM
Study NCT ID:
NCT00073957
Status:
COMPLETED
Last Update Posted:
2018-01-23
First Post:
2003-12-10
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Y 90 Ibritumomab Tiuxetan &Rituximab Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Sponsor:
Beth Israel Deaconess Medical Center
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
2003P000182
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None